Delivery Order 75N91024D00004-75N91024F00002
Award Date
9/20/24
Potential Completion Date
3/19/26
Potential Value
$1.1M
Federal Agency
National Cancer Institute
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Houston, TX 77030, USA
Solicitation Procedures
Multiple Award, Fair Opportunity
Number Of Offers Received
1
Legislative Mandate
Employment Eligibility Verification
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a $1,162,921.53 firm-fixed-price delivery order contract awarded by the National Cancer Institute (NCI) to The University of Texas M.D. Anderson Cancer Center (MD Anderson) for the "Evaluation of Real-Time Metabolic Imaging Biomarkers for Detection of Pancreatic Premalignant Lesions". The contract is part of the larger "PREVENT Preclinical Drug Development Program: Preclinical Efficacy & Intermediate Biomarkers" indefinite delivery, indefinite quantity (IDIQ)...
This is a delivery order issued under the National Institutes of Health (NIH) PREVENT Preclinical Drug Development Program (PREVENT) indefinite delivery, indefinite quantity (IDIQ) contract. The award was made to the University of Texas MD Anderson Cancer Center, a component of the University of Texas System, to conduct preclinical testing of CD73 inhibitors for pancreatic cancer immunoprevention. The potential value of this task order is $1,191,330.00, with a completion date of December 20,...
This federal contract award, valued at $1,272,481.00, was issued by the National Cancer Institute to The University of Texas M.D. Anderson Cancer Center, a child entity of the University of Texas System. The contract is part of the "PREVENT Preclinical Drug Development Program (PREVENT)" and is focused on "TARGETING THE A2B ADENOSINE RECEPTOR FOR IMMUNOPREVENTION OF PANCREATIC CANCER." It is a firm fixed-price delivery order contract with a completion date of March 14,...
This is a firm fixed price delivery order contract awarded by the National Cancer Institute (NCI), a component of the National Institutes of Health (NIH), to The University of Texas MD Anderson Cancer Center (MD Anderson) in the amount of $400,411.43. The contract was issued under the PREVENT Cancer Program (PREVENT) contract vehicle and supports the PRECLINICAL PREVENT CANCER PROGRAM: PRECLINICAL EFFICACY AND INTERMEDIATE ENDPOINT BIOMARKERS project with a period of performance through...
This is a firm fixed-price delivery order contract awarded by the National Institutes of Health (NIH) National Cancer Institute to the University of Texas MD Anderson Cancer Center, a component of the University of Texas System, for a "Targeted Casein Kinase Inhibition as a Breast Cancer Prevention" research project. The $505,743.00 contract, which has no set-aside designation, was awarded on June 20, 2017 and is scheduled for completion by December 31, 2019. The contract falls under...
This is a Delivery Order issued against the National Institutes of Health's PREVENT Cancer Program (PREVENT) Indefinite Delivery/Indefinite Quantity (IDIQ) contract. The award, valued at $4,445.48, was made to the University of Texas MD Anderson Cancer Center, a component of the University of Texas System, for a "CONTRACT ORIENTATION AND KICKOFF MEETING" related to the PRECLINICAL PREVENT CANCER PROGRAM initiative. The award has an ultimate completion date of December 31, 2015 and does...
This federal contract award from the National Cancer Institute (NCI) to the University of Texas MD Anderson Cancer Center (MD Anderson) is for the "CANCER PREVENTION BY ALPHA ENOLASE VACCINATION" project, which is part of the NCI's "PRECLINICAL PREVENT CANCER PROGRAM: PRECLINICAL EFFICACY AND INTERMEDIATE ENDPOINT BIOMARKERS" initiative. The $547,718.84 firm fixed price delivery order contract was awarded on September 15, 2016 with a completion date of February 14, 2020. MD...
The National Cancer Institute awarded a Firm Fixed Price Delivery Order contract to the University of Texas MD Anderson Cancer Center, a component of the University of Texas System, valued at $1,121,090.00. The contract is part of the PREVENT Preclinical Drug Development Program and supports preclinical efficacy and intermediate endpoint biomarker studies targeting the PARP pathway for the prevention of breast cancer. The contract has a period of performance through May 31, 2026 and is not set...
This is a delivery order awarded by the Department of Health and Human Services National Institutes of Health National Cancer Institute to The University of Texas MD Anderson Cancer Center, a component of the University of Texas System. The award is part of the PREVENT Cancer Program (PREVENT), which supports preclinical research on preventing triple-negative breast cancer. The $774,513.14 firm-fixed-price task order covers research targeted at the RXR pathway for the prevention of...
This is a delivery order awarded by the National Cancer Institute (NCI) to The University of Texas MD Anderson Cancer Center (MD Anderson) under the "PREVENT Preclinical Drug Development Program (PREVENT)" Indefinite Delivery Contract (IDC). The delivery order, valued at $840,820.00, is for a project titled "TARGETING STAT3 TO PREVENT HEPATOCELLULAR CARCINOMA (HCC) ASSOCIATED WITH NON-ALCOHOLIC STEATOHEPATITIS (NASH)". The project is focused on preclinical efficacy and...